相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Chimeric antigen receptor T-cells, bispecific antibodies, and antibody-drug conjugates for multiple myeloma: An update
Arjun Lakshman et al.
AMERICAN JOURNAL OF HEMATOLOGY (2022)
Risk stratified management approaches for smouldering multiple myeloma: clinical research becomes clinical practice
Sagar Lonial et al.
Lancet Haematology (2022)
Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group
Noopur S Raje et al.
Lancet Haematology (2022)
Neutralizing Antibody Testing in Patients With Multiple Myeloma Following COVID-19 Vaccination
Evangelos Terpos et al.
JAMA ONCOLOGY (2022)
Cancer Statistics, 2021
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial
Thierry Facon et al.
LANCET ONCOLOGY (2021)
Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group
Philippe Moreau et al.
LANCET ONCOLOGY (2021)
Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma
Nikhil C. Munshi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentage
Carlos Fernandez de Larrea et al.
BLOOD CANCER JOURNAL (2021)
Oral ixazomib, lenalidomide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma
Thierry Facon et al.
BLOOD (2021)
Preclinical activity and determinants of response of the GPRC5DxCD3 bispecific antibody talquetamab in multiple myeloma
Christie P. M. Verkleij et al.
BLOOD ADVANCES (2021)
Teclistamab, a B-cell maturation antigenxCD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study
Saad Z. Usmani et al.
LANCET (2021)
Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial
Philippe Moreau et al.
LANCET (2021)
Ciltacabtagene autoleucel, a B-cell maturation antigendirected chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study
Jesus G. Berdeja et al.
LANCET (2021)
Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial
Philippe Moreau et al.
LANCET ONCOLOGY (2021)
Iberdomide (CC-220) is a potent cereblon E3 ligase modulator with antitumor and immunostimulatory activities in lenalidomide- and pomalidomide-resistant multiple myeloma cells with dysregulated CRBN
Chad C. Bjorklund et al.
LEUKEMIA (2020)
Depth of Response to Daratumumab (DARA), Lenalidomide, Bortezomib, and Dexamethasone (RVd) Improves over Time in Patients (pts) with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Griffin Study Update
Peter M. Voorhees et al.
BLOOD (2020)
Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial
Maria-Victoria Mateos et al.
LANCET (2020)
Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study
Sagar Lonial et al.
LANCET ONCOLOGY (2020)
BiTEing the Tumor
Shaji Kumar et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial
Maria-Victoria Mateos et al.
LANCET HAEMATOLOGY (2020)
Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study
Meletios Dimopoulos et al.
LANCET (2020)
Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial
Shaji K. Kumar et al.
LANCET ONCOLOGY (2020)
Multiple myeloma current treatment algorithms
S. Vincent Rajkumar et al.
BLOOD CANCER JOURNAL (2020)
International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM)
Maria-Victoria Mateos et al.
BLOOD CANCER JOURNAL (2020)
Early Versus Late Autologous Stem Cell Transplant in Newly Diagnosed Multiple Myeloma: Long-Term Followup Analysis of the IFM 2009 Trial
Aurore Perrot et al.
BLOOD (2020)
TAK-573, an Anti-CD38/Attenuated Ifnα Fusion Protein, Has Clinical Activity and Modulates the Ifnα Receptor (IFNAR) Pathway in Patients with Relapsed/Refractory Multiple Myeloma
Dan T. Vogl et al.
BLOOD (2020)
Once-weekly versus twice-weekly carfilzomib in patients with newly diagnosed multiple myeloma: a pooled analysis of two phase I/II studies
Sara Bringhen et al.
HAEMATOLOGICA (2019)
MAIA under the microscope - bringing trial design into focus
Prashant Kapoor et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2019)
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
Noopur Raje et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma
T. Facon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study
Philippe Moreau et al.
LANCET (2019)
Surrogate endpoints in randomised controlled trials: a reality check
Shaji Kumar et al.
LANCET (2019)
International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders
Jens Hillengass et al.
LANCET ONCOLOGY (2019)
Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma
Ajai Chari et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Autologous Transplantation, Consolidation, and Maintenance Therapy in Multiple Myeloma: Results of the BMT CTN 0702 Trial
Edward A. Stadtmauer et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial
Meletios A. Dimopoulos et al.
LANCET (2019)
Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial
Graham H. Jackson et al.
LANCET ONCOLOGY (2019)
Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study
Michel Attal et al.
LANCET (2019)
Detection and prevalence of monoclonal gammopathy of undetermined significance: a study utilizing mass spectrometry-based monoclonal immunoglobulin rapid accurate mass measurement
David Murray et al.
BLOOD CANCER JOURNAL (2019)
Bortezomib before and after high-dose therapy in myeloma: long-term results from the phase III HOVON-65/GMMGHD-4 trial
H. Goldschmidt et al.
LEUKEMIA (2018)
Improvement in Overall Survival With Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
David S. Siegel et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Once-weekly carfilzomib, pomalidomide, and low-dose dexamethasone for relapsed/refractory myeloma: a phase I/II study
Sara Bringhen et al.
LEUKEMIA (2018)
Prognostic significance of interphase FISH in monoclonal gammopathy of undetermined significance
Arjun Lakshman et al.
LEUKEMIA (2018)
The multiple myelomas - current concepts in cytogenetic classification and therapy
Shaji K. Kumar et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Long-Term Follow-up of Monoclonal Gammopathy of Undetermined Significance
Robert A. Kyle et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria
Arjun Lakshman et al.
BLOOD CANCER JOURNAL (2018)
Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma
Meletios A. Dimopoulos et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Bendamustine, lenalidomide and dexamethasone (BRd) has high activity as 2nd-line therapy for relapsed and refractory multiple myeloma - a phase II trial
Ulrich J. M. Mey et al.
BRITISH JOURNAL OF HAEMATOLOGY (2017)
Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid on Skeletal Events in Patients With Bone Metastases A Randomized Clinical Trial
Andrew L. Himelstein et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2017)
Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial
Meletios A. Dimopoulos et al.
LANCET ONCOLOGY (2017)
Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma
Michel Attal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Prevalence of myeloma precursor state monoclonal gammopathy of undetermined significance in 12 372 individuals 10-49 years old: a population-based study from the National Health and Nutrition Examination Survey
O. Landgren et al.
BLOOD CANCER JOURNAL (2017)
High somatic mutation and neoantigen burden are correlated with decreased progression-free survival in multiple myeloma
A. Miller et al.
BLOOD CANCER JOURNAL (2017)
Whole-body computed tomography versus conventional skeletal survey in patients with multiple myeloma: a study of the International Myeloma Working Group
J. Hillengass et al.
BLOOD CANCER JOURNAL (2017)
Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma
Shaji Kumar et al.
BLOOD (2017)
Elotuzumab plus lenalidomide/dexamethasone for relapsed or refractory multiple myeloma: ELOQUENT-2 follow-up and post-hoc analyses on progression-free survival and tumour growth
Meletios A. Dimopoulos et al.
BRITISH JOURNAL OF HAEMATOLOGY (2017)
Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma
Ajai Chari et al.
BLOOD (2017)
A phase 1b study of isatuximab plus lenalidomide and dexamethasone for relapsed/refractory multiple myeloma
Thomas Martin et al.
BLOOD (2017)
VTD is superior to VCD prior to intensive therapy in multiple myeloma: results of the prospective IFM2013-04 trial
Philippe Moreau et al.
BLOOD (2016)
Multiple myeloma-translation of trial results into reality
Philippe Moreau et al.
LANCET (2016)
Lenalidomide plus dexamethasone versus observation in patients with high-risk smouldering multiple myeloma (QuiRedex): long-term follow-up of a randomised, controlled, phase 3 trial
Maria-Victoria Mateos et al.
LANCET ONCOLOGY (2016)
Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study
Meletios A. Dimopoulos et al.
LANCET ONCOLOGY (2016)
International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma
Shaji Kumar et al.
LANCET ONCOLOGY (2016)
Progress in Myeloma - A Monoclonal Breakthrough
S. Vincent Rajkumar et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma
P. Moreau et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma
M. A. Dimopoulos et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma
Antonio Palumbo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Lenalidomide (LEN) maintenance (MNTC) after high-dose melphalan and autologous stem cell transplant (ASCT) in multiple myeloma (MM): A meta-analysis (MA) of overall survival (OS).
Michel Attal et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma
Jatin J. Shah et al.
BLOOD (2015)
Clinical course and prognosis of non-secretory multiple myeloma
Sagar S. Chawla et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2015)
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
Antonio Palumbo et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma
Sagar Lonial et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma
A. Keith Stewart et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma
H. M. Lokhorst et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Characteristics of exceptional responders to lenalidomide-based therapy in multiple myeloma
T. Vu et al.
BLOOD CANCER JOURNAL (2015)
Interpretation of cytogenetic results in multiple myeloma for clinical practice
A. M. Rajan et al.
BLOOD CANCER JOURNAL (2015)
Phase II study of bendamustine, bortezomib and dexamethasone as second-line treatment for elderly patients with multiple myeloma: the Intergroupe Francophone du Myelome 2009-01 trial
Philippe Rodon et al.
HAEMATOLOGICA (2015)
Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study
Paul G. Richardson et al.
BLOOD (2014)
Carfilzomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed multiple myeloma: a multicenter, phase 2 study
Sara Bringhen et al.
BLOOD (2014)
Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study
Shaji K. Kumar et al.
LANCET ONCOLOGY (2014)
International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma
S. Vincent Rajkumar et al.
LANCET ONCOLOGY (2014)
Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients
S. K. Kumar et al.
LEUKEMIA (2014)
Consolidation and maintenance therapy with lenalidomide, bortezomib and dexamethasone (RVD) in high-risk myeloma patients
A. K. Nooka et al.
LEUKEMIA (2014)
Racial disparities in the prevalence of monoclonal gammopathies: a population-based study of 12 482 persons from the National Health and Nutritional Examination Survey
O Landgren et al.
LEUKEMIA (2014)
Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Myeloma
Lotfi Benboubker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Autologous Transplantation and Maintenance Therapy in Multiple Myeloma
A. Palumbo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells
Jan Kroenke et al.
SCIENCE (2014)
The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins
Gang Lu et al.
SCIENCE (2014)
Progression in Smoldering Myeloma Is Independently Determined by the Chromosomal Abnormalities del(17p), t(4;14), Gain 1q, Hyperdiploidy, and Tumor Load
Kai Neben et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial
Jesus San Miguel et al.
LANCET ONCOLOGY (2013)
Impact of primary molecular cytogenetic abnormalities and risk of progression in smoldering multiple myeloma
S. V. Rajkumar et al.
LEUKEMIA (2013)
Lenalidomide plus Dexamethasone for High-Risk Smoldering Multiple Myeloma
Maria-Victoria Mateos et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Phase II Clinical and Correlative Study Of Carfilzomib, Lenalidomide, and Dexamethasone Followed By Lenalidomide Extended Dosing (CRD-R) Induces High Rates Of MRD Negativity In Newly Diagnosed Multiple Myeloma (MM) Patients
Neha Korde et al.
BLOOD (2013)
A Randomized Phase 3 Trial Of Melphalan-Lenalidomide-Prednisone (MPR) Or Cyclophosphamide-Prednisone-Lenalidomide (CPR) Vs Lenalidomide Plus Dexamethsone (Rd) In Elderly Newly Diagnosed Multiple Myeloma Patients
Antonio Palumbo et al.
BLOOD (2013)
Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide
Alessandra Larocca et al.
BLOOD (2012)
Trisomies in multiple myeloma: impact on survival in patients with high-risk cytogenetics
Shaji Kumar et al.
BLOOD (2012)
Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma
Shaji Kumar et al.
BLOOD (2012)
A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma
Andrzej J. Jakubowiak et al.
BLOOD (2012)
Bortezomib Induction and Maintenance Treatment in Patients With Newly Diagnosed Multiple Myeloma: Results of the Randomized Phase III HOVON-65/GMMG-HD4 Trial
Pieter Sonneveld et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study
S. K. Kumar et al.
LEUKEMIA (2012)
Incidence of Monoclonal Gammopathy of Undetermined Significance and Estimation of Duration Before First Clinical Recognition
Terry M. Therneau et al.
MAYO CLINIC PROCEEDINGS (2012)
Continuous Lenalidomide Treatment for Newly Diagnosed Multiple Myeloma
Antonio Palumbo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma
Michel Attal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
Philip L. McCarthy et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease
Martha Q. Lacy et al.
BLOOD (2011)
Approach to the treatment of multiple myeloma: a clash of philosophies
S. Vincent Rajkumar et al.
BLOOD (2011)
Aspirin, Warfarin, or Enoxaparin Thromboprophylaxis in Patients With Multiple Myeloma Treated With Thalidomide: A Phase III, Open-Label, Randomized Trial
Antonio Palumbo et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Multiple myeloma and the road to personalised medicine
Stephen J. Russell et al.
LANCET ONCOLOGY (2011)
Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial
Amrita Krishnan et al.
LANCET ONCOLOGY (2011)
Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study
Philippe Moreau et al.
LANCET ONCOLOGY (2011)
Incidence of extramedullary disease in patients with multiple myeloma in the era of novel therapy, and the activity of pomalidomide on extramedullary myeloma
K. Detweiler Short et al.
LEUKEMIA (2011)
Total Therapy 3 for multiple myeloma: prognostic implications of cumulative dosing and premature discontinuation of VTD maintenance components, bortezomib, thalidomide, and dexamethasone, relevant to all phases of therapy
Frits van Rhee et al.
BLOOD (2010)
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma
Paul G. Richardson et al.
BLOOD (2010)
Initial versus deferred melphalan-prednisone therapy for asymptomatic multiple myeloma stage I - A randomized study
Martin Hjorth et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2010)
Bortezomib-Melphalan-Prednisone-Thalidomide Followed by Maintenance With Bortezomib-Thalidomide Compared With Bortezomib-Melphalan-Prednisone for Initial Treatment of Multiple Myeloma: A Randomized Controlled Trial
Antonio Palumbo et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study
Michele Cavo et al.
LANCET (2010)
Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: a retrospective population-based cohort study
Angela Dispenzieri et al.
LANCET (2010)
Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial
Maria-Victoria Mateos et al.
LANCET ONCOLOGY (2010)
Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial
S. Vincent Rajkumar et al.
LANCET ONCOLOGY (2010)
Stem cell collection in patients with de novo multiple myeloma treated with the combination of bortezomib and dexamethasone before autologous stem cell transplantation according to IFM 2005-01 trial
P. Moreau et al.
LEUKEMIA (2010)
Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM)
M. Q. Lacy et al.
LEUKEMIA (2010)
Identification of a Primary Target of Thalidomide Teratogenicity
Takumi Ito et al.
SCIENCE (2010)
Reduced-intensity allogeneic transplantation for myeloma: reality bites
A. Keith Stewart
BLOOD (2009)
A monoclonal gammopathy precedes multiple myeloma in most patients
Brendan M. Weiss et al.
BLOOD (2009)
Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study
Ola Landgren et al.
BLOOD (2009)
Multicenter, Phase I, Dose-Escalation Trial of Lenalidomide Plus Bortezomib for Relapsed and Relapsed/Refractory Multiple Myeloma
Paul G. Richardson et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Pomalidomide (CC4047) Plus Low-Dose Dexamethasone As Therapy for Relapsed Multiple Myeloma
Martha Q. Lacy et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders
A. Dispenzieri et al.
LEUKEMIA (2009)
The molecular characterization and clinical management of multiple myeloma in the post-genome era
Y. Zhou et al.
LEUKEMIA (2009)
Patterns of monoclonal gammopathy of undetermined significance and multiple myeloma in various ethnic/racial groups: support for genetic factors in pathogenesis
O. Landgren et al.
LEUKEMIA (2009)
Is the international staging system superior to the Durie-Salmon staging system? A comparison in multiple myeloma patients undergoing autologous transplant
P. N. Hari et al.
LEUKEMIA (2009)
Acquisition of a multidrug-resistant phenotype with a proteasome inhibitor in multiple myeloma
D. Gutman et al.
LEUKEMIA (2009)
Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial
C. B. Reeder et al.
LEUKEMIA (2009)
Management of Newly Diagnosed Symptomatic Multiple Myeloma: Updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines
Shaji K. Kumar et al.
MAYO CLINIC PROCEEDINGS (2009)
Many facets of bortezomib resistance/susceptibility
Shaji Kumar et al.
BLOOD (2008)
VTD combination therapy with bortezomib-thalidomide-dexamethasone is highly effective in advanced and refractory multiple myeloma
M. Pineda-Roman et al.
LEUKEMIA (2008)
Treatment of myeloma: Cure vs control
S. Vincent Rajkumar
MAYO CLINIC PROCEEDINGS (2008)
Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma
A. Palumbo et al.
LEUKEMIA (2008)
Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma:: Combination therapy improves time to progression
Robert Z. Orlowski et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma
S. Kumar et al.
LEUKEMIA (2007)
Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3
Bart Barlogie et al.
BRITISH JOURNAL OF HAEMATOLOGY (2007)
Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma
Robert A. Kyle et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Impact of prior thalidomide (T) therapy on the efficacy of pegylated liposomal doxorubicin (PLD) and bortezomib (B) in relapsed/refractory multiple myeloma (RRMM)
P. Sonneveld et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study
Michele Cavo et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
A comparison of allografting with autografting for newly diagnosed myeloma
Benedetto Bruno et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Biochemical markers of bone turnover in diagnosis of myeloma bone disease
Omer Dizdar et al.
AMERICAN JOURNAL OF HEMATOLOGY (2007)
Myeloma bone disease: Pathogenetic mechanisms and clinical assessment
Franco Silvestris et al.
LEUKEMIA RESEARCH (2007)
Elimination of the need for urine studies in the screening algorithm for monoclonal gammopathies by using serum immunofixation and free light chain assays
Jerry A. Katzmann et al.
MAYO CLINIC PROCEEDINGS (2006)
Prevalence of monoclonal gammopathy of undetermined significance
RA Kyle et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: Final results of phase III US intergroup trial S9321
B Barlogie et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma
SV Rajkumar et al.
BLOOD (2005)
Bortezomib or high-dose dexamethasone for relapsed multiple myeloma
PG Richardson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
International staging system for multiple myeloma
PR Greipp et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Proteasome inhibition as a novel therapeutic target in human cancer
SV Rajkumar et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Incidence of multiple myeloma in Olmsted County, Minnesota - Trend over 6 decades
RA Kyle et al.
CANCER (2004)
Clinical course of patients with relapsed multiple myeloma
SK Kumar et al.
MAYO CLINIC PROCEEDINGS (2004)
Single versus double autologous stem-cell transplantation for multiple myeloma
M Attal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Transplantation for multiple myeloma:: who, when, how often?: High-dose therapy in multiple myeloma
J Bladé
BLOOD (2003)
New insights into the pathophysiology of multiple myeloma
S Seidl et al.
LANCET ONCOLOGY (2003)
High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma
JA Child et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Management of multiple myeloma: a systematic review and critical appraisal of published studies
A Kumar et al.
LANCET ONCOLOGY (2003)
Review of 1027 patients with newly diagnosed multiple myeloma
RA Kyle et al.
MAYO CLINIC PROCEEDINGS (2003)
Genomic abnormalities in monoclonal gammopathy of undetermined significance
R Fonseca et al.
BLOOD (2002)
A long-term study of prognosis in monoclonal gammopathy of undetermined significance
RA Kyle et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Multiple myeloma: Evolving genetic events and host interactions
WM Kuehl et al.
NATURE REVIEWS CANCER (2002)
Chromosome translocations in multiple myeloma
PL Bergsagel et al.
ONCOGENE (2001)